| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Vantictumab | OMP-18R5; anti-Fzd7 | Phase 1 Clinical | Oncomed Pharmaceuticals Inc, Bayer AG | Solid tumours; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |

BettinastraBe 30, 60325 Frankfurt am Main



